一项随机、三盲、安慰剂对照临床试验评估健康成人中对Typhim Vi和PPSV23疫苗的免疫反应:PREP研究
该随机三盲安慰剂对照试验纳入210名18-40岁健康成人,接种PPSV23、Typhim Vi或安慰剂,在4周内多时点采集血样、可穿戴设备及问卷数据。结果显示PPSV23组炎症反应更强,两种疫苗诱导的免疫反应不同,提示疫苗可作为研究不同病原体相关炎症反应的模型。
要点
- PPSV23组接种后2天CRP显著高于其他两组(均p<0.05)。
- PPSV23组接种后7天嗜碱性粒细胞、IL-10、IL-12p40和MIG显著高于其他两组(均p<0.05)。
- Typhim Vi组接种后7天单核细胞和MPV显著低于安慰剂组(均p<0.05)。
核心结论
- PPSV23组表现出更高的炎症特征,提示PPSV23诱导的免疫反应强于Typhim Vi。
- 两种疫苗诱导的免疫反应不同,表明疫苗有潜力作为研究不同传染性病原体相关炎症反应的模型。
研究设计与样本
- 随机、三盲、安慰剂对照临床试验(NCT05346302),纳入210名18-40岁健康成人。
- 经过2周基线期后,参与者分别接种PPSV23、Typhim Vi或安慰剂。
- 在4周内多个时间点采集血样、可穿戴设备数据和问卷。
主要发现
- PPSV23组接种后2天CRP显著高于其他两组(均p<0.05)。
- PPSV23组接种后7天嗜碱性粒细胞、IL-10、IL-12p40和MIG显著高于其他两组(均p<0.05)。
- PPSV23组接种后7天MIP-1β显著低于安慰剂组(p<0.05)。
- Typhim Vi组接种后7天单核细胞和MPV显著低于安慰剂组(均p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid and early identification of emergent infections is essential for delivering prompt clinical care. To advance the development of algorithms for the clinical management of infection identification, we performed a vaccination clinical trial to investigate the potential of using vaccination as a model for studying mild inflammation responses associated with different infections (NCT05346302). We collected data at various time points over 4 weeks from blood samples, wearable devices, and questionnaires. Following a 2-week baseline period, 210 healthy participants, aged 18-40 years, were administered either a Pneumococcal Polysaccharide vaccine (PPSV23), Typhoid Vi Polysaccharide vaccine (Typhim Vi), or placebo. In longitudinal analyses of blood biomarkers, we found that CRP was significantly higher at 2 days post-vaccination, whereas basophils, IL-10, IL-12p40, and MIG were significantly higher at 7 days post-vaccination in the PPSV23 group compared to both other groups (all p < 0.05). MIP-1β was significantly lower in the PPSV23 group than in the placebo group, while monocytes and MPV were significantly lower in the Typhim Vi group than in the placebo group at 7 days post-vaccination (all p < 0.05). The PPSV3 group showed a higher inflammatory profile, suggesting that PPSV23 induces a stronger immune response compared to Typhim Vi. The distinct immune responses induced by the two vaccines indicate the potential for utilizing vaccines as models for studying inflammation responses associated with different infectious pathogens.
引用
- Wang C, Damiano RJ, Ruebush LE, et al. A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study. Vaccine. 2024. PMID: 39245584. doi:10.1016/j.vaccine.2024.126292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。